Neuronetics, Inc. STIM
1.47 USD -0.16 (-9.57%)
Nov 12, 2026, 2:04 PM EST
1.39 Day range 1.61
0.80 52-week range 3.44
- YTD
- +6.16%
- 1 year
- -32.18%
News
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) stock increased by 13.2% to $1.29 during Wednesday's pre-market session. The company's market cap stands at $5.4 million. The company's, Q2 earnings came…
globenewswire.com Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common Stock MALVERN, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the pricing of its previously announced underwritten public offering of its common…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 13.9% to $2.2 during Tuesday's after-market session. The company's market cap stands at $73.3 million. Longeveron (NASDAQ:LGVN) stock…
benzinga.com Neuronetics Announces Credit Agreement Amendments And Public Offering Of Shares; Size Not Disclosed Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics"), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook…
globenewswire.com Neuronetics Announces Proposed Public Offering of Common Stock MALVERN, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology…
benzinga.com B. Riley Securities Maintains Buy on Neuronetics, Raises Price Target to $6 B. Riley Securities analyst Madison El-Saadi maintains Neuronetics (NASDAQ:STIM) with a Buy and raises the price target from $5 to $6.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…
benzinga.com Neuronetics Q3 2026 Earnings Call Transcript Neuronetics (NASDAQ:STIM) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Neuronetics Q3 EPS $(0.02) Beats $(0.09) Estimate, Sales $41.962M Beat $40.425M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.09) by 77.78 percent. This is a 84.62 percent increase over losses of $(0.13)…
benzinga.com Neuronetics Affirms FY2026 Sales Guidance of $160.000M-$164.000M vs $162.025M Est Neuronetics (NASDAQ:STIM) affirms FY2026 sales outlook from $160.000 million-$164.000 million to $160.000 million-$164.000 million vs $162.025 million estimate.- benzinga.com B. Riley Securities Initiates Coverage On Neuronetics with Buy Rating, Announces Price Target of $5 B. Riley Securities analyst Madison El-Saadi initiates coverage on Neuronetics (NASDAQ:STIM) with a Buy rating and announces Price Target of $5.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's pre-market session. The market value of their outstanding shares is at $43.4 million. Organigram Global…
benzinga.com Neuronetics Narrows FY2026 Sales Guidance from $160.000M-$166.000M to $160.000M-$164.000M vs $161.125M Est Neuronetics (NASDAQ:STIM) narrows FY2026 sales outlook from $160.000 million-$166.000 million to $160.000 million-$164.000 million vs $161.125 million estimate.
benzinga.com Neuronetics Q2 EPS $(0.05) Beats $(0.13) Estimate, Sales $41.568M Beat $40.175M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.13) by 58.33 percent. This is a 66.67 percent increase over losses of $(0.15)…- benzinga.com Neuronetics Appoints Nir Naor CFO, Effective July 23, Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional…
benzinga.com Why Is Neuronetics Stock Soaring Monday? BTIG initiates coverage on Neuronetics (STIM) with a Buy rating and $5 target as shares surge 28%. Read the details here.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's regular session. The company's market cap stands at $33.0 million. Advanced Biomed (NASDAQ:ADVB) stock…
- benzinga.com BTIG Initiates Coverage On Neuronetics with Buy Rating, Announces Price Target of $5 BTIG analyst Sam Eiber initiates coverage on Neuronetics (NASDAQ:STIM) with a Buy rating and announces Price Target of $5.
benzinga.com Neuronetics Collaborates With ANT Neuro To Expand NeuroStar Advanced Therapy System Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth…- benzinga.com Full Transcript: Neuronetics Q1 2026 Earnings Call
benzinga.com Neuronetics Affirms FY2026 Sales Guidance of $160.000M-$166.000M vs $162.467M Est Business OutlookFor the second quarter of 2026, the Company expects total revenue growth in the mid-single digits.For the full year 2026, Neuronetics continues to expect:Total revenue between $160…- benzinga.com Neuronetics Q1 EPS $(0.16) Beats $(0.17) Estimate, Sales $34.454M Beat $34.183M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.17) by 5.88 percent. This is a 23.81 percent increase over losses of $(0.21)…
benzinga.com Earnings Scheduled For May 5, 2026 
benzinga.com Deal Dispatch: Unilever Buys Grüns, Pershing Square Eyes Universal Music Group, Saks Global Reorganization Plan This week's deal activity spans gaming, healthcare, energy, and private equity, with activist sales pushes and a slew of bankruptcies.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Neuronetics Initiates Workforce Reduction Impacting Up To 5% Of Employees, Expects ~$200K Restructuring Charges And ~$2.5-$3M Annualized Savings On April 2, 2026, the Company initiated a workforce reduction, which it expects to be completed by mid-year 2026, that will impact up to 5% of its employees. The reduction is part of a broader effort…- benzinga.com Neuronetics CFO Steven E. Pfanstiel To Depart, Effective May 1; Reiterates Q1, FY26 Outlook Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from…
- benzinga.com Canaccord Genuity Maintains Buy on Neuronetics, Lowers Price Target to $3 Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and lowers the price target from $7 to $3.
- benzinga.com Neuronetics Sees FY2026 Sales $160.000M-$166.000M vs $164.167M Est Neuronetics (NASDAQ:STIM) sees FY2026 sales of $160.000 million-$166.000 million vs $164.167 million analyst estimate.
- benzinga.com Neuronetics Q4 EPS $(0.10) Beats $(0.11) Estimate, Sales $41.777M Beat $40.667M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 6.54 percent. This is a 70.59 percent increase over losses of $(0.34)…
- benzinga.com Earnings Scheduled For March 17, 2026
- benzinga.com Peering Into Neuronetics Inc's Recent Short Interest
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Teradata Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket 
benzinga.com Neuronetics (STIM) Stock Rises 41% After Hours: What's Going On? Neuronetics shares jumped 41% in after-hours trading following strong preliminary fourth-quarter 2025 revenue results.- benzinga.com Neuronetics Reports Q4 Preliminary Revenue $41.8M, FY25 Revenue $149.2M Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the…
benzinga.com Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November - benzinga.com Neuronetics Lowers FY2025 Sales Guidance from $149.000M-$155.000M to $147.000M-$150.000M vs $151.030M Est Neuronetics (NASDAQ:STIM) lowers FY2025 sales outlook from $149.000 million-$155.000 million to $147.000 million-$150.000 million vs $151.030 million estimate.
benzinga.com Neuronetics Q3 EPS $(0.13) Misses $(0.10) Estimate, Sales $37.297M Miss $38.055M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10) by 26.21 percent. This is a 70.45 percent increase over losses of…
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com New York Medicaid To Cover Neuronetics' TMS Therapy For Major Depressive Disorder Starting October 2025 Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth…
- benzinga.com Canaccord Genuity Maintains Buy on Neuronetics, Lowers Price Target to $7 Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and lowers the price target from $8 to $7.
- benzinga.com Neuronetics Affirms FY2025 Sales Guidance of $149.000M-$155.000M vs $150.673M Est Neuronetics (NASDAQ:STIM) affirms FY2025 sales outlook from $149.000 million-$155.000 million to $149.000 million-$155.000 million vs $150.673 million estimate.
- benzinga.com Neuronetics Sees Q3 Sales $37.000M-$39.000M vs $38.395M Est Neuronetics (NASDAQ:STIM) sees Q3 sales of $37.000 million-$39.000 million vs $38.395 million analyst estimate.
- benzinga.com Neuronetics Q2 EPS $(0.15) Misses $(0.08) Estimate, Sales $38.108M Beat $36.612M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.08) by 94.81 percent. This is a 54.55 percent increase over losses of…
- benzinga.com Earnings Scheduled For August 5, 2025
- benzinga.com Neuronetics Publishes Real-World Data Showing Antidepressant Effects Of NeuroStar TMS In Adolescents And Young Adults Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth…